Inspire Medical Systems (INSP)
(Delayed Data from NYSE)
$126.10 USD
+1.56 (1.25%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $126.01 -0.09 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Inspire Medical Systems, Inc. has a PEG ratio of 1.98 compared to the Medical Info Systems industry's PEG ratio of 2.78.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
INSP 126.10 +1.56(1.25%)
Will INSP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for INSP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INSP
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Butterfly Network, Inc. (BFLY) Reports Q2 Loss, Misses Revenue Estimates
INSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Doximity (DOCS) Reports Next Week: Wall Street Expects Earnings Growth
Can Sustained Product Demand Drive HIMS Stock Before Q2 Earnings?
Inspire Medical Systems (INSP) Expected to Beat Earnings Estimates: Should You Buy?
Other News for INSP
Uncovering Potential: Inspire Medical Systems's Earnings Preview
Inspire Medical Systems Q2 2025 Earnings Preview
Baron Discovery Fund Q2 2025 Commentary
TimesSquare Global Small Cap Strategy Q2 2025 Commentary
Apnimed says sleep apnea drug meets primary endpoint in Phase 3 trial